NL-OMON28691
Recruiting
Not Applicable
The effects of structured follow-up from primary care for patients during their cancer journey. A randomized controlled trial.
niversitair Medisch Centrum Utrecht (UMCU)0 sites150 target enrollmentTBD
ConditionsCancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cancer
- Sponsor
- niversitair Medisch Centrum Utrecht (UMCU)
- Enrollment
- 150
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Newly diagnosed with the following types of cancer: breast cancer, colorectal cancer, gynaecologic cancer, lung cancer or melanoma.
- •2\) Cancer therapy is to be initiated with curative intent.
Exclusion Criteria
- •1\) Major psychiatric disease and personality disorders.
- •2\) Unable to fill in questionnaires.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Influence of structured follow up in First seizure clinic on anxiety of parents and children after first, unprovoked seizure- a randomized, controlled pilot studyEpileptic seizureR56.8Other and unspecified convulsionsDRKS00011736Klinik für Neuropädiatrie und Muskelerkrankungen, Zentrum für Kinder- und Jugendheilkunde des Universitätsklinikums Freiburg40
Completed
Not Applicable
A prospective study of appropriate follow-up interval for high-risk group of branch duct type intraductal papillary mucinous neoplasms of the pancreasJPRN-UMIN000016989Sendai City Medical Center155
Enrolling By Invitation
Not Applicable
Structured Follow-up Intervention on Glucose Status After Pancreatic Cancer SurgeryPancreas CancerDiabetesNCT06774170Dokuz Eylul University40
Active, not recruiting
Phase 1
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis Cong-term Follow-up of prior study participantsMedDRA version: 14.0Level: PTClassification code 10019641Term: Hepatic cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2006-006529-25-DESchering-Plough Research Institute1,954
Active, not recruiting
Not Applicable
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis CEUCTR2006-006529-25-PTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.2,800